Discovering and developing proprietary NME prodrugs

Targeting improved therapies for pain, ADHD and other CNS indications

Addressing the epidemic of opioid abuse in the United States – KP201/APAP

About KemPharm

KemPharm is engaged in the discovery and development of proprietary NME prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

KemPharm’s intent is to develop prodrugs that have improved properties over approved drugs and address unmet medical needs in large, established markets.

more »

KP201/APAP

KP201/APAP, KemPharm’s most advanced product candidate, is currently being developed for the treatment of acute-moderate to moderately severe pain.  Consisting of KP201, KemPharm’s prodrug of hydrocodone, formulated in combination with acetaminophen, KP201/APAP is designed to deter tampering and abuse.

more »